Role of Lifeguard β-isoform in the development of breast cancer

Dastagir,Nadjib; Lazaridis,Andrea; Dastagir,Khaled; Reimers,Kerstin; Vogt,Peter  M.; Bucan,Vesna

doi:10.3892/or.2014.3363

Role of Lifeguard β-isoform in the development of breast cancer

Authors:
- Nadjib Dastagir
- Andrea Lazaridis
- Khaled Dastagir
- Kerstin Reimers
- Peter M. Vogt
- Vesna Bucan
View Affiliations

Affiliations: Department of Plastic, Hand and Reconstructive Surgery, Hannover Medical School, D-30659 Hannover, Germany
Published online on: July 25, 2014 https://doi.org/10.3892/or.2014.3363
Pages: 1335-1340
Copyright: © Dastagir et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the last century there has been great progress in the treatment of breast cancer by improving drug and radiation therapy as well as surgical techniques. Despite this development, breast cancer remains a major cause of death among women in Europe and the US. The cause of breast cancer at the cellular level is still not fully understood. In the present study, we investigated the expression of the Lifeguard β-isoform in breast cancer tissues. In contrast to Lifeguard, the β‑isoform has one transmembrane domain less, which is the last of seven (99 bp), and due to this we suspect that the Lifeguard β-isoform exhibits a different function. We determined the expression and function of the β-isoform of Lifeguard in breast cancer cell lines (MCF-7 and MDA-MB-231), a human breast epithelial cell line (MCF10A) and in breast tumour tissue sections. Western blotting, PCR arrays and immunofluorescence were used to investigate the expression of Lifeguard and its β-isoform. Moreover, we investigated the ability of Lifeguard β-isoform expression to inhibit apoptosis induced by Fas. Our results indicated that Lifeguard β-isoform is strongly expressed in breast tumour tissues. More notably, we demonstrated that Fas sensitivity was reduced in the MCF10A breast cells expressing the Lifeguard β-isoform. Taken together, our findings indicate the role of the Lifeguard β-isoform as an anti‑apoptotic protein and provide further evidence of the potential of the Lifeguard β-isoform as a target for the development of novel therapeutic strategies.

View Figures

View References

1	Somia NV, Schmitt MJ, Vetter DE, Van Antwerp D, Heinemann SF and Verma IM: LFG: an anti-apoptotic gene that provides protection from Fas-mediated cell death. Proc Natl Acad Sci USA. 96:12667–12672. 1999. View Article : Google Scholar : PubMed/NCBI
2	Fernandez M, Segura MF, Sole C, Colino A, Comella JX and Cena V: Lifeguard/neuronal membrane protein 35 regulates Fas ligand-mediated apoptosis in neurons via microdomain recruitment. J Neurochem. 103:190–203. 2007.PubMed/NCBI
3	Bucan V, Reimers K, Choi CY, Eddy MT and Vogt PM: The anti-apoptotic protein lifeguard is expressed in breast cancer cells and tissues. Cell Mol Biol Lett. 15:296–310. 2010. View Article : Google Scholar : PubMed/NCBI
4	Reimers K, Choi CY, Bucan V and Vogt PM: The Bax inhibitor-1 (BI-1) family in apoptosis and tumourigenesis. Curr Mol Med. 8:148–156. 2008. View Article : Google Scholar : PubMed/NCBI
5	Reimers K, Choi CY, Bucan V and Vogt PM: The growth-hormone inducible transmembrane protein (Ghitm) belongs to the Bax inhibitory protein-like family. Int J Biol Sci. 3:471–476. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bucan V, Choi CY, Lazaridis A, Vogt PM and Reimers K: Silencing of anti-apoptotic transmembrane protein lifeguard sensitizes solid tumour cell lines MCF-7 and SW872 to peri-fosine-induced cell death activation. Oncol Lett. 2:419–422. 2011.PubMed/NCBI
7	Nguyen A, Rosner A, Milovanovic T, et al: Wnt pathway component LEF1 mediates tumour cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression. Int J Oncol. 27:949–956. 2005.PubMed/NCBI
8	Hu L, Smith TF and Goldberger G: LFG: a candidate apoptosis regulatory gene family. Apoptosis. 14:1255–1265. 2009. View Article : Google Scholar : PubMed/NCBI
9	Beier CP, Wischhusen J, Gleichmann M, et al: FasL (CD95L/APO-1L) resistance of neurons mediated by phosphatidylinositol 3-kinase-Akt/protein kinase B-dependent expression of lifeguard/neuronal membrane protein 35. J Neurosci. 25:6765–6774. 2005. View Article : Google Scholar : PubMed/NCBI
10	Satoh A, Bryant SV and Gardiner DM: Regulation of dermal fibroblast dedifferentiation and redifferentiation during wound healing and limb regeneration in the Axolotl. Dev Growth Differ. 50:743–754. 2008. View Article : Google Scholar : PubMed/NCBI
11	Grzmil M, Thelen P, Hemmerlein B, Schweyer S, Voigt S, Mury D and Burfeind P: Bax inhibitor-1 is overexpressed in prostate cancer and its specific down-regulation by RNA interference leads to cell death in human prostate carcinoma cells. Am J Pathol. 163:543–552. 2003. View Article : Google Scholar : PubMed/NCBI
12	Grzmil M, Kaulfuss S, Thelen P, Hemmerlein B, Schweyer S, Obenauer S, Kang TW and Burfeind P: Expression and functional analysis of Bax inhibitor-1 in human breast cancer cells. J Pathol. 208:340–349. 2006. View Article : Google Scholar : PubMed/NCBI
13	Tanaka R, Ishiyama T, Uchihara T, Inadome Y, Iijima T, Morishita Y, Kano J, Goya T and Noguchi M: Expression of the Bax inhibitor-1 gene in pulmonary adenocarcinoma. Cancer. 106:648–653. 2006. View Article : Google Scholar : PubMed/NCBI
14	Villalva C, Trempat P, Greenland C, Thomas C, Girard JP, Moebius F, Delsol G and Brousset P: Isolation of differentially expressed genes in NPM-ALK-positive anaplastic large cell lymphoma. Br J Haematol. 188:791–798. 2002. View Article : Google Scholar : PubMed/NCBI
15	Keane MM, Ettenberg SA, Lowrey GA, Russell EK and Lipkowitz S: Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56:4791–4798. 1996.PubMed/NCBI
16	Sjöström J, Blomqvist C, von Boguslawski K, et al: The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer. Clin Cancer Res. 8:811–816. 2002.PubMed/NCBI
17	Botti C, Buglioni S, Benevolo M, et al: Altered expression of FAS system is related to adverse clinical outcome in stage I–II breast cancer patients treated with adjuvant anthracycline-based chemotherapy. Clin Cancer Res. 10:1360–1365. 2004.PubMed/NCBI
18	Mottolese M, Buglioni S, Bracalenti C, et al: Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer. 89:127–132. 2000. View Article : Google Scholar : PubMed/NCBI
19	Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D, Friese K and Thiesen HJ: FasL: Fas ratio - a prognostic factor in breast carcinomas. Cancer Res. 60:822–828. 2000.PubMed/NCBI
20	Qin LX and Tang ZY: The prognostic molecular markers in hepatocellular carcinoma. World J Gastroenterol. 8:385–392. 2002.PubMed/NCBI
21	Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R, Nishiyama T, Takahashi K and Tomita Y: Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer. 93:544–551. 2005. View Article : Google Scholar : PubMed/NCBI
22	Onodera H, Mori A, Nagayama S, Fujimoto A, Tachibana T, Yonenaga Y and Tsuruyama T: Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer. Int J Colorectal Dis. 20:477–484. 2005. View Article : Google Scholar : PubMed/NCBI
23	Sträter J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T and Möller P: Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut. 54:661–665. 2005.PubMed/NCBI
24	Lee WC, Yu MC and Chen MF: Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy. World J Surg. 28:792–796. 2004. View Article : Google Scholar : PubMed/NCBI
25	Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K and Chayama K: Fas and Fas ligand: expression and soluble circulating levels in bile duct carcinoma. Oncol Rep. 11:1183–1186. 2004.PubMed/NCBI
26	Kanauchi H, Wada N, Ginzinger DG, Yu M, Wong MG, Clark OH and Duh QY: Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumours. J Clin Endocrinol Metab. 88:3690–3693. 2003. View Article : Google Scholar : PubMed/NCBI
27	Chin YR and Toker A: The actin-bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration. Mol Cell. 38:333–344. 2010. View Article : Google Scholar : PubMed/NCBI
28	Yoeli-Lerner M, Yiu GK, Rabinovitz I, Erhardt P, Jauliac S and Toker A: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol Cell. 20:539–550. 2005. View Article : Google Scholar : PubMed/NCBI
29	Liu H, Radisky DC, Nelson CM, Zhang H, Fata JE, Roth RA and Bissell MJ: Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumourigenic role for TSC2. Proc Natl Acad Sci USA. 103:4134–4139. 2006. View Article : Google Scholar : PubMed/NCBI
30	Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al: Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res. 63:196–206. 2003.PubMed/NCBI
31	Tagliabue E, Castiglioni F, Ghirelli C, et al: Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem. 275:5388–5394. 2000. View Article : Google Scholar : PubMed/NCBI
32	Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A and Bernardini R: Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res. 61:3002–3008. 2001.PubMed/NCBI
33	Descamps S, Toillon RA, Adriaenssens E, et al: Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem. 276:17864–17870. 2001. View Article : Google Scholar : PubMed/NCBI
34	Hass R and Bertram C: Characterization of human breast cancer epithelial cells (HBCEC) derived from long term cultured biopsies. J Exp Clin Cancer Res. 28:1272009. View Article : Google Scholar : PubMed/NCBI